KMT2Ar MRD level distribution and outcomes posttransplant. (A) Pretransplant KMT2A::X MRD distribution according to fusion-gene type. (B) KMT2A::X MRD detection pre-HCT is significantly associated with increased relapse incidence. CIR with nonrelapse mortality as competing risk according to pre-HCT MRD status. Significance of test is assessed using Gray's test. (C-D) Kaplan-Meier estimates of (C) RFS and (D) OS according to pre-HCT MRD status. (E) Relapse-free survival according to pretransplant KMT2A::X MRD threshold range: MRD-negative (<0.001%), 0.001% to <0.1%, 0.1% to <1%, and ≥1%. (F) RFS in patients who received transplant in CR1 according to MRD status (n = 50). CI, confidence interval; neg, negative; pos, positive.